Internal Hemipelvectomy for primary bone sarcomas using intraoperative patient specific instruments- the next step in limb salvage concept.
3D pre-operative planning
Anatomical models
Internal hemipelvectomy
Patient specific instruments (PSI)
Pelvic bone tumors
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
08
02
2022
accepted:
26
10
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
During pelvic Sarcoma resections, Surgeons often struggle to obtain negative margins while minimizing collateral damage and maintaining limb function. These complications are usually due to the complex anatomy of the pelvis. Here we present an accurate 3D surgical approach, including pre-operative printing of models and intraoperative patient-specific instruments (PSIs) for optimizing pelvic sarcoma resections. This single-center retrospective study (N = 11) presents surgical, functional, and oncological outcomes of patients (average age 14.6 +/- 7.6 years, 4 males) who underwent pelvic sarcoma resections using a 3D surgical approach between 2016 and 2021. All patients were followed up for at least 24 months (mean = 38.9 +/- 30.1 months). Our results show promising surgical, oncological, and functional outcomes. Using a 3D approach, 90.9% had negative margins, and 63.6% did not require reconstruction surgery. The average estimated blood loss was 895.45 ± 540.12 cc, and the average surgery time was 3:38 ± 0.05 hours. Our results revealed no long-term complications. Three patients suffered from short-term complications of superficial wound infections. At 24 month follow up 72.7% of patients displayed no evidence of disease. The average Musculoskeletal Tumor Society (MSTS) score at 12 months was 22.81. 3D technology enables improved accuracy in tumor resections, allowing for less invasive procedures and tailored reconstruction surgeries, potentially leading to better outcomes in function and morbidity. We believe that this approach will enhance treatments and ease prognosis for patients diagnosed with pelvic sarcoma and will become the standard of care in the future.
Sections du résumé
BACKGROUND
BACKGROUND
During pelvic Sarcoma resections, Surgeons often struggle to obtain negative margins while minimizing collateral damage and maintaining limb function. These complications are usually due to the complex anatomy of the pelvis. Here we present an accurate 3D surgical approach, including pre-operative printing of models and intraoperative patient-specific instruments (PSIs) for optimizing pelvic sarcoma resections.
METHODS
METHODS
This single-center retrospective study (N = 11) presents surgical, functional, and oncological outcomes of patients (average age 14.6 +/- 7.6 years, 4 males) who underwent pelvic sarcoma resections using a 3D surgical approach between 2016 and 2021. All patients were followed up for at least 24 months (mean = 38.9 +/- 30.1 months).
RESULTS
RESULTS
Our results show promising surgical, oncological, and functional outcomes. Using a 3D approach, 90.9% had negative margins, and 63.6% did not require reconstruction surgery. The average estimated blood loss was 895.45 ± 540.12 cc, and the average surgery time was 3:38 ± 0.05 hours. Our results revealed no long-term complications. Three patients suffered from short-term complications of superficial wound infections. At 24 month follow up 72.7% of patients displayed no evidence of disease. The average Musculoskeletal Tumor Society (MSTS) score at 12 months was 22.81.
CONCLUSION
CONCLUSIONS
3D technology enables improved accuracy in tumor resections, allowing for less invasive procedures and tailored reconstruction surgeries, potentially leading to better outcomes in function and morbidity. We believe that this approach will enhance treatments and ease prognosis for patients diagnosed with pelvic sarcoma and will become the standard of care in the future.
Identifiants
pubmed: 36424560
doi: 10.1186/s12891-022-05918-1
pii: 10.1186/s12891-022-05918-1
pmc: PMC9685900
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012Informations de copyright
© 2022. The Author(s).
Références
Cancer Control. 2011 Jul;18(3):171-6
pubmed: 21666579
Musculoskelet Surg. 2015 Dec;99(3):237-42
pubmed: 26238978
Orthop Traumatol Surg Res. 2016 Oct;102(6):807-11
pubmed: 27318805
J Orthop Sci. 2018 Nov;23(6):1045-1050
pubmed: 30037470
Sarcoma. 2018 Nov 13;2018:4065846
pubmed: 30538600
Clin Orthop Relat Res. 2018 Mar;476(3):499-508
pubmed: 29529631
3D Print Med. 2018 Nov 26;4(1):12
pubmed: 30649645
World J Surg Oncol. 2016 Sep 21;14(1):249
pubmed: 27729037
J Clin Oncol. 1992 Jan;10(1):5-15
pubmed: 1370176
Int J Surg Oncol (N Y). 2017 May;2(4):e07
pubmed: 29238756
Clin Orthop Relat Res. 2017 Mar;475(3):686-695
pubmed: 27020434
J Am Coll Surg. 1995 Jul;181(1):43-8
pubmed: 7599770
Int Orthop. 2009 Jun;33(3):751-6
pubmed: 19089426
Sarcoma. 2010;2010:125162
pubmed: 21127723
Clin Orthop Relat Res. 2014 Jan;472(1):349-59
pubmed: 23975252
Sarcoma. 2014;2014:842709
pubmed: 25100921
Clin Orthop Relat Res. 2020 Feb;478(2):290-302
pubmed: 31580267
J Bone Oncol. 2021 Oct 18;31:100396
pubmed: 34786331
Surg Clin North Am. 2016 Oct;96(5):901-14
pubmed: 27542634
Ann Plast Surg. 2015 Mar;74(3):342-9
pubmed: 23903084
Bone Joint J. 2016 Apr;98-B(4):555-63
pubmed: 27037440
Int J Comput Assist Radiol Surg. 2016 Feb;11(2):307-16
pubmed: 26148694
Orthop Traumatol Surg Res. 2019 Jun;105(4):781-787
pubmed: 30982774
Ann Biomed Eng. 2014 Jan;42(1):205-13
pubmed: 23963884
J Bone Joint Surg Am. 1999 Mar;81(3):317-25
pubmed: 10199269
Clin Orthop Relat Res. 2012 Mar;470(3):712-27
pubmed: 21748513
J Clin Oncol. 2003 Jan 15;21(2):334-41
pubmed: 12525527
J Clin Orthop Trauma. 2017 Jul-Sep;8(3):249-253
pubmed: 28951642
3D Print Med. 2022 Feb 1;8(1):7
pubmed: 35106697
Adv Exp Med Biol. 2018;1093:315-326
pubmed: 30306491
Med Pediatr Oncol. 1995 Jan;24(1):6-12
pubmed: 7968796
Transl Pediatr. 2021 Mar;10(3):474-484
pubmed: 33850806
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
J Pediatr Surg. 2014 Oct;49(10):1500-4
pubmed: 25280655